Akebia Therapeutics, Inc. (AKBA) Financial Statements (2024 and earlier)

Company Profile

Business Address 245 FIRST STREET
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:90,466149,800268,690147,694321,640317,792
Cash and cash equivalents90,466149,800228,698147,449104,64470,156
Short-term investments    245216,751247,636
Other undisclosed cash, cash equivalents, and short-term investments   39,992 245 
Receivables40,28450,87526,85338,86416,66634,216
Inventory, net of allowances, customer advances and progress billings21,56838,19561,017116,349114,245 
Inventory21,56838,19561,017116,349114,245 
Other undisclosed current assets32,86433,14014,8776,62615,7246,348
Total current assets:185,182272,010371,437309,533468,275358,356
Noncurrent Assets
Operating lease, right-of-use asset29,15833,85226,87629,038
Property, plant and equipment5,2146,7548,62210,3808,0233,617
Intangible assets, net (including goodwill)131,128163,180199,223346,265383,206 
Goodwill59,04455,05355,05355,05355,053 
Intangible assets, net (excluding goodwill)72,084108,127144,170291,212328,153 
Other noncurrent assets5,37249,75437,98175,985137,0362,274
Total noncurrent assets:170,872253,540272,702461,668528,2655,891
TOTAL ASSETS:356,054525,550644,139771,201996,540364,247
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities93,798138,044171,932168,288193,71359,439
Accounts payable18,02133,58841,30839,21742,7966,998
Accrued liabilities75,777104,456130,624129,071150,91752,441
Deferred revenue 3,73820,90615,21439,830
Debt32,00097,543  15,000 
Deferred revenue and credits84,910
Contract with customer, liability56,980
Total current liabilities:129,536256,493187,146208,118265,693144,349
Noncurrent Liabilities
Long-term debt and lease obligation34,07833,703120,999103,333  
Long-term debt, excluding current maturities34,078 96,37875,805  
Liabilities, other than long-term debt128,966103,99985,95663,34388,288100,567
Deferred revenue and credits100,545
Deferred revenue43,29621,47425,34533,120
Contract with customer, liability55,709
Deferred rent credit     3,006
Customer refund liability 40,992     
Other liabilities15,71782,52560,61130,22329,57322
Operating lease, liability28,96133,70324,62127,528
Other undisclosed noncurrent liabilities58,24454,8992,4201,6506,631 
Total noncurrent liabilities:221,288192,601209,375168,32694,919100,567
Total liabilities:350,824449,094396,521376,444360,612244,916
Equity
Equity, attributable to parent5,23076,456247,618394,757635,928119,331
Common stock21111 
Additional paid in capital1,562,2471,536,8001,425,1151,188,8101,150,583493,823
Accumulated other comprehensive income (loss)6613 (261)(442)
Accumulated deficit(1,557,025)(1,460,351)(1,177,511)(794,054)(514,395)(374,050)
Total equity:5,23076,456247,618394,757635,928119,331
TOTAL LIABILITIES AND EQUITY:356,054525,550644,139771,201996,540364,247

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues292,484213,578295,307335,001207,742177,984
Revenue, net177,984
Cost of revenue(85,568)(153,394)(295,908)(145,336)(7,768) 
Cost of goods and services sold(85,568)(153,394)(180,381)(108,935)(6,251) 
Gross profit:206,91660,184(601)189,665199,974177,984
Operating expenses(287,695)(325,502)(375,841)(475,953)(378,135)(257,901)
Operating loss:(80,779)(265,318)(376,442)(286,288)(178,161)(79,917)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
3,1462,4141,856(794)81204
Interest and debt expense (906)     
Loss from continuing operations before equity method investments, income taxes:(78,539)(262,904)(374,586)(287,082)(178,080)(79,713)
Other undisclosed income (loss) from continuing operations before income taxes(15,687)(19,936)(8,871)7926,154 
Loss from continuing operations before income taxes:(94,226)(282,840)(383,457)(286,290)(171,926)(79,713)
Income tax benefit    6,63128,338 
Loss from continuing operations:(94,226)(282,840)(383,457)(279,659)(143,588)(79,713)
Loss before gain (loss) on sale of properties:(282,840)(383,457)(279,659)(143,588)(79,713)
Net loss:(94,226)(282,840)(383,457)(279,659)(143,588)(79,713)
Other undisclosed net income attributable to parent     2,799
Net loss available to common stockholders, diluted:(94,226)(282,840)(383,457)(279,659)(143,588)(76,914)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(94,226)(282,840)(383,457)(279,659)(143,588)(79,713)
Comprehensive loss:(94,226)(282,840)(383,457)(279,659)(143,588)(79,713)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent (7)132611812,399
Comprehensive loss, net of tax, attributable to parent:(94,226)(282,847)(383,444)(279,398)(143,407)(77,314)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: